ABSI at a glance
Absci Corp (ABSI, SEC CIK 1672688) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 11, 2026 and Form 4 insider filings as recently as September 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Absci Corp (ABSI) reported revenue of $2.8 million (down 38.2% from FY2024) and a net loss of $115.2 million. Diluted EPS was -$0.84.
- As of June 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Absci Corp (ABSI) shares worth $1.1 billion in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Szela Mary T on June 30, 2026 of 12,900 shares at $11.54 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.8M
- −38.2% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 29 funds
- $1.1B · −1 vs prior quarter
- Latest 8-K
- Aug 11, 2026
- Item 2.02 · Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $0.3M, down 46% YoY from $0.6M
- Operating loss $34.2M vs $31.4M YoY; operating margin -11,402% vs -5,294%
- Best-performing program ABS-201; interim safety data favorable, half-life at least 65 days
- Cash, equivalents, and securities $201.1M; operating cash use $53.9M vs $38.7M YoY
- June offering raised $93.6M; Phase 2 endometriosis trial anticipated Q4 2026
Risk Factors
- No material-change statement; filing reiterates 10-K risks without identifying a newly added trigger
- Partner-license risk: no partner had licensed related intellectual property for clinical or commercial use as of August 11, 2026
- FDA compliance risk: staffing changes or shortages could delay IND reviews, regulations, guidance, or enforcement
- Clinical-development risk: ABS-201 Phase 1/2a trial continued MAD dosing while other programs remained research or preclinical
- Liquidity risk: $201.1 million in cash, equivalents, and marketable securities expected to fund at least 12 months
AI summary of the ABSI 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results covered the quarter ended June 30, 2026
- Financial details and management commentary provided in Exhibit 99.1 press release
Item 8.01: Other Events
- Absci released an August 11, 2026 investor presentation with internal pipeline program updates
- Presentation provides investors current visibility into drug-development priorities and pipeline progress
Item EX-99.1: Item EX-99.1
- Positive interim Phase 1 ABS-201 data: favorable safety profile and estimated half-life of at least 65 days
- Pattern hair-loss interim proof-of-concept data expected second half 2026, with full readout targeted for early 2027
Item 1.01: Entry into a Material Definitive Agreement
- $100.0 million gross equity offering: 13,495,277 shares at $7.41 each
- Approximately $93.5 million net proceeds after underwriting discounts and expenses
Item 8.01: Other Events
- June 24, 2026 press release announced pricing of Absci’s offering
- Offering terms and potential financing impact are contained in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- $100 million gross equity financing through 13,495,277 shares priced at $7.41 each
- Dilution from newly issued shares, with underwriting discounts and offering expenses reducing net proceeds
Item 8.01: Other Events
- Interim Phase 1 data released for ABS-201 in the HEADLINE™ trial
- Clinical update creates a potential valuation catalyst for Absci’s drug-development pipeline
Item EX-99.1: Item EX-99.1
- Positive Phase 1 safety signal: 32 participants across 150–1800 mg SAD cohorts, with no serious adverse events
- ABS-201 half-life estimated at least 65 days, supporting potential two- or three-dose administration over six months
AI summaries of ABSI 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ABSI
Don't miss the next ABSI filing
- Alerts as it files. A push when ABSI files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ABSI, by share count.
- Ask anything. An AI agent that reads every ABSI filing and answers with sources.
ABSI alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Jonasson Zachariah | F | Aug 31, 2026 | 8,320 | $8.71 |
| Somaratne Ransi Mudalinayake | A | Aug 3, 2026 | 383,000 | - |
| Szela Mary T | Buy | Jun 30, 2026 | 12,900 | $11.54 |
| McClain Sean | F | Jun 24, 2026 | 59,896 | $10.07 |
| Pangalos Menelas N | A | Jun 4, 2026 | 39,800 | - |
| VAN HOUTEN FRANS | A | Jun 4, 2026 | 10,100 | - |
| Szela Mary T | A | Jun 4, 2026 | 10,100 | - |
| Rabinovitsj Daniel A | A | Jun 4, 2026 | 39,800 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $4.5M | $2.8M |
| Operating Income | - | -$108.9M | -$120.3M |
| Net Income | -$110.6M | -$103.1M | -$115.2M |
| Op. Margin | - | -2401.6% | -4297.0% |
| Net Margin | - | -2274.1% | -4113.7% |
| Balance Sheet | |||
| Total Assets | $217.3M | $213.6M | $216.3M |
| Equity | - | $179.1M | $189.4M |
| ROE | - | -57.6% | -60.8% |
| Per Share | |||
| EPS | $-1.20 | $-0.94 | $-0.84 |
| Cash Flow | |||
| Operating CF | - | -$72.4M | -$92.9M |
| CapEx | $860K | $404K | $1.1M |
Source: XBRL data in Absci Corp (ABSI)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ABSI share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 29 | $1.15B |
| Q1 2026 | 30 | $241.4M |
| Q4 2025 | 25 | $281.0M |
| Q3 2025 | 26 | $190.8M |
| Q2 2025 | 25 | $143.4M |
| Q1 2025 | 22 | $117.0M |
| Q4 2024 | 18 | $93.4M |
| Q3 2024 | 15 | $55.0M |
- D.E. Shaw & Co+4.59M (+706%)
- Ameriprise Financial+3.81M (+120%)
- FMR LLC (Fidelity)+2.86M (+13%)
- Two Sigma Investments+2.59M (+90%)
- T. Rowe Price Group+1.37M (+1167%)
- Millennium Management−948.7K (-79%)
- ARK Investment Management−800.9K (-6%)
- Citadel Advisors LLC−301.6K (-75%)
- JPMorgan Chase & Co−2.3K (-1%)
- Dimensional Fund Advisors−271 (-0%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 190 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ABSI filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 1, 2026 | - | - | - |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 7, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 8-K | Jun 24, 2026 | - | Analysis | - |
| 8-K | Jun 24, 2026 | - | Analysis | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | Jun 5, 2026 | - | Analysis | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-K | Mar 24, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 24, 2026 | - | - | - |
| 4 | Mar 16, 2026 | - | - | - |
| 4 | Mar 16, 2026 | - | - | - |
| 4 | Mar 16, 2026 | - | - | - |
Related Health Care companies
- CRL · Charles River LaboratoriesServices-Commercial Physical & Biological Research
- INCY · IncyteServices-Commercial Physical & Biological Research
- IQV · IQVIAServices-Commercial Physical & Biological Research
- MXCT · MAXCYTE, INC.Services-Commercial Physical & Biological Research
- NRC · NATIONAL RESEARCH CORPServices-Commercial Physical & Biological Research
- OABI · OmniAb, Inc.Services-Commercial Physical & Biological Research
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
ABSI SEC filings: frequently asked questions
Which institutions hold ABSI stock?
As of June 30, 2026, the largest Absci Corp (ABSI) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($294.5 million), ARK Investment Management ($149.8 million), BlackRock ($141.1 million), State Street Corp ($93.8 million), Ameriprise Financial ($81.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ABSI's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Absci Corp (ABSI) reported revenue of $2.8 million (down 38.2% from FY2024) and a net loss of $115.2 million. Diluted EPS was -$0.84. The figures come from the XBRL data in the 10-K.
What did ABSI report in its latest 8-K?
Absci Corp (ABSI) filed an 8-K on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 8.01 (Other Events). Q2 2026 results covered the quarter ended June 30, 2026.
What are the latest ABSI SEC filings?
Absci Corp (ABSI) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 11, 2026 and a Form 4 insider filing on September 1, 2026.
What is ABSI's SEC CIK number?
Absci Corp (ABSI)'s SEC Central Index Key (CIK) is 1672688. EDGAR lists every ABSI filing under that number.
Ask anything about ABSI
The research agent reads ABSI's filings, financials, insider trades and 13F holders, then answers with sources.